CADTH recommends that Olumiant be reimbursed by public drug plans for the treatment of adults with severe alopecia areata (AA) […]
This rapid review updates the evidence for early biologic treatment versus conventional step-up therapy for patients with luminal Crohn disease,
This rapid review examines the clinical efficacy, effectiveness, and safety of BRAF and MEK inhibitors as a treatment for patients
Canada’s Drug Agency recommends that Crysvita be reimbursed by public drug plans for the treatment of X-linked hypophosphatemia (XLH) in
Vital Statistics Rapid Release Reports are based on the current flow of vital statistics data from state vital records offices
Women make up over half of the U.S. population, yet research on women’s health conditions, including those that are female
We recommend that Tibsovo in combination with azacitidine be reimbursed by public drug plans for the treatment of adult patients
Registration No: 771800548 Contact Number : +91-8249516996
